<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618002</url>
  </required_header>
  <id_info>
    <org_study_id>SalemAnaesth2022 LemborexZop</org_study_id>
    <nct_id>NCT05618002</nct_id>
  </id_info>
  <brief_title>Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients</brief_title>
  <official_title>Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salem Anaesthesia Pain Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salem Anaesthesia Pain Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational crossover study of 150 consenting adult patients who are undergoing&#xD;
      chronic pain management. For insomnia treatment, each patient ingests prescribed doses of&#xD;
      Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special&#xD;
      validated sleep diary to collect data including pain score, sleep score, sleep duration,&#xD;
      sleep medication type, and adverse effects. Each patient completes the diary for 3 continuous&#xD;
      weeks. Pain is measured using the numeric pain rating scale. Sleep score is measured using&#xD;
      the Likert sleep scale. A change in the pain or sleep scores by 2-points is considered&#xD;
      significant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: Chronic pain is usually associated with insomnia. The objective of this clinical&#xD;
      study is to compare the safety and efficacy of Lemborexant or Zopiclone or Clonidine; for the&#xD;
      management of chronic insomnia in patients with chronic pain.&#xD;
&#xD;
      Methods: Prospective observational crossover study of 150 consenting adult patients who are&#xD;
      undergoing chronic pain management. For insomnia treatment, each patient ingests prescribed&#xD;
      doses of Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a&#xD;
      special validated sleep diary to collect data including pain score, sleep score, sleep&#xD;
      duration, sleep medication type, and adverse effects. Each patient completes the diary for 3&#xD;
      continuous weeks. Pain is measured using the numeric pain rating scale. Sleep score is&#xD;
      measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points is&#xD;
      considered significant. Data analyzed with IBM® SPSS® Statistics 25 (IBM Corp, Armonk, NY);&#xD;
      using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value&#xD;
      &lt;0.05 is considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2022</start_date>
  <completion_date type="Anticipated">October 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep quality score, objective measurement using the validated Likert sleep scale</measure>
    <time_frame>3 weeks</time_frame>
    <description>Sleep quality score, using the Likert sleep scale of 0 to 10, low scores indicate poor sleep, high scores indicate better sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score, objective measurement using the validated Numeric Pain Rating scale</measure>
    <time_frame>3 weeks</time_frame>
    <description>Pain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Insomnia</condition>
  <condition>Chronic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant</intervention_name>
    <description>For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.</description>
    <other_name>Zopiclone</other_name>
    <other_name>Clonidine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult chronic pain clinic patients who have severe chronic insomnia; and undergoing&#xD;
        medication treatment for insomnia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult chronic pain patients&#xD;
&#xD;
          -  good treatment compliance&#xD;
&#xD;
          -  severe chronic insomnia&#xD;
&#xD;
          -  failure of non-pharmacologic sleep therapy&#xD;
&#xD;
          -  regular zopiclone therapy for 3 months or more&#xD;
&#xD;
          -  regular sleep diary&#xD;
&#xD;
          -  regular pain diary&#xD;
&#xD;
          -  informed consent for diary review&#xD;
&#xD;
          -  consent for clinical record quality assurance review&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  obstructive sleep apnoea&#xD;
&#xD;
          -  body mass index (BMI) ≥40&#xD;
&#xD;
          -  organ insufficiency&#xD;
&#xD;
          -  cognitive disorder&#xD;
&#xD;
          -  inability to provide consent&#xD;
&#xD;
          -  major neuropsychiatric disorder&#xD;
&#xD;
          -  unreliable diary&#xD;
&#xD;
          -  cannabis use&#xD;
&#xD;
          -  regular alcohol intake&#xD;
&#xD;
          -  stimulant use&#xD;
&#xD;
          -  substance abuse&#xD;
&#xD;
          -  poor treatment compliance&#xD;
&#xD;
          -  high dose opioid&#xD;
&#xD;
          -  gabapentinoid use&#xD;
&#xD;
          -  sedative use&#xD;
&#xD;
          -  mild insomina&#xD;
&#xD;
          -  irregular zopiclone intake&#xD;
&#xD;
          -  regular zopiclone therapy for less than 3 months&#xD;
&#xD;
          -  previous adverse/allergic reactions to clonidine or zopiclone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olu Bamgbade, MD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salem Anaesthesia Pain Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olu Bamgbade, MD,FRCPC</last_name>
    <phone>+17786286600</phone>
    <email>salem.painclinic@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Salem Anaesthesia Pain Clinic</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3S 7J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olu Bamgbade, MD,FRCPC</last_name>
      <phone>+17786286600</phone>
      <email>salem.painclinic@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, Murphy-Akpieyi O, Fadire A, Soni NK, Mumporeze L. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. J Clin Sleep Med. 2022 Jun 1;18(6):1565-1571. doi: 10.5664/jcsm.9930.</citation>
    <PMID>35112665</PMID>
  </results_reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>April 13, 2023</last_update_submitted>
  <last_update_submitted_qc>April 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedative</keyword>
  <keyword>Hypnotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Lemborexant</mesh_term>
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

